series a
Stage
1
Investors
About
Infex Therapeutics (InfexTx) acquires, develops and licenses innovative anti-infective drugs to treat pandemic and drug-resistant infections. The company is based at Alderley Park in the North West of England and is advancing clinical programmes (eg. RESP-X/INFEX702) into Phase IIa while raising development funding.
Explore INFEX Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.